新型生物制剂治疗炎症性肠病的研究进展

摘要

炎症性肠病(IBD)是一种慢性非特异性肠道炎症性疾病,传统的治疗药物包括氨基水杨酸类药物、糖皮质激素、免疫抑制剂等,长期使用不良反应多、复发率高,且对重度患者疗效不佳.研究表明生物制剂在IBD诱导和维持缓解、促进黏膜愈合、改善患者生活质量等方面效果显著.随着对IBD发病机制研究的深入,新型生物制剂的研发已广泛开展.本文就新型生物制剂治疗IBD的研究进展作一综述.%Inflammatory bowel disease (IBD) is a chronic,non-specific intestinal inflammatory disease.Traditional drug therapy includes aminosalicylates,glucocorticoids and immunosuppressive agents,and their long-term use will induce multiple side effects,and having high recurrence rate and poor efficacy in critically ill patients.Studies have shown that biological agents are effective in inducing and maintaining remission in patients with IBD,promoting mucosal healing,and improving the quality of life.With the in-depth study of pathogenesis of IBD,researches on the development of novel biological agents have been performed widespreadly.This article reviewed the advances in study on novel biological agents in treatment of IBD.